Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression

Am J Obstet Gynecol. 1995 Dec;173(6):1829-34. doi: 10.1016/0002-9378(95)90436-0.

Abstract

Objective: We previously described vascular invasion-associated changes, defined as the presence of vascular invasion or perivascular lymphocytic infiltrates, as key prognostic indicators in stage I endometrioid carcinoma. The current study was undertaken to examine the prognostic value of HER-2/neu expression in relation to other factors, including vascular invasion-associated changes, in surgical stage I endometrioid carcinoma.

Study design: Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic acid ploidy, and HER-2/neu expression. The latter was examined by an objective computerized quantitative immunohistochemical system.

Results: By univariate analysis many factors were found to correlate with outcome, including age, tumor grade, depth of invasion, ploidy, HER-2/neu expression, and vascular invasion-associated changes. By multivariate analysis only vascular invasion-associated changes, aneuploidy, and HER-2/neu overexpression were found to independently correlate with survival. Stratification of patients on the basis of these three features revealed survival rates of 100%, 92%, and 60% when none, one, and two or three features were present, respectively.

Conclusion: This study suggests that HER-2/neu expression correlated with outcome independent of other factors in endometrial carcinoma and may aid in estimating prognosis. The prognostic value of HER-2/neu overexpression independent of vascular invasion suggests that this factor may operate by increasing the ability of tumor cells to grow at a distal site once vascular invasion occurs.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma / chemistry*
  • Carcinoma / genetics
  • Carcinoma / pathology*
  • Carcinoma / therapy
  • Combined Modality Therapy
  • Endometrial Neoplasms / chemistry*
  • Endometrial Neoplasms / genetics
  • Endometrial Neoplasms / pathology*
  • Endometrial Neoplasms / therapy
  • Female
  • Humans
  • Hysterectomy
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Proteins / analysis*
  • Neoplasm Staging
  • Ploidies
  • Prognosis
  • Radiotherapy, Adjuvant
  • Random Allocation
  • Receptor, ErbB-2 / analysis*
  • Retrospective Studies
  • Survival Analysis

Substances

  • Neoplasm Proteins
  • Receptor, ErbB-2